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ABSTRACT
Invasive lobular carcinoma comprises 10–15%
of all breast cancers and is increasingly recog-
nised as a distinct and understudied disease
compared with the predominant histological
subtype, invasive ductal carcinoma. Hallmarks
of invasive lobular carcinoma include E-cad-
herin loss, leading to discohesive morphology
with cells proliferating in single-file strands and
oestrogen receptor positivity, with favourable
response to endocrine therapy. This review
summarises the distinct histological and
molecular features of invasive lobular carci-
noma with focus on diagnostic challenges and
the impact on surgical management and
medical therapy. Emphasis is placed on recent
advances in our understanding of the unique
molecular biology of lobular breast cancer and
how this is optimising our therapy approach in
the clinic.
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Key Summary Points
This review provides a summary of the
distinct features of lobular breast cancer
and how these impact current clinical
decision-making
An overview of the key diagnostic, surgical
and medical therapy challenges in lobular
breast cancer is presented
Key clinical trials of targeted and
immunomodulatory therapies in lobular
breast cancer are outlined
The article emphasises the functional
implications of lobular breast cancer’s
unique molecular biology and their
potential impact on therapy in the future
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m9.figshare.11358614.
J. Luveta  S. J. Johnston (&)
Division of Cancer and Stem Cells, Nottingham
Breast Cancer Research Centre, School of Medicine,
University of Nottingham, Nottingham, UK
e-mail: simon.johnston@nottingham.ac.uk
J. Luveta  D. M. Heery  S. J. Johnston
Gene Regulation and RNA Biology, School of
Pharmacy, University of Nottingham, Nottingham,
UK
R. M. Parks  K.-L. Cheung
Division of Medical Sciences and Graduate Entry
Medicine, Nottingham Breast Cancer Research
Centre, School of Medicine, University of
Nottingham, Nottingham, UK
Oncol Ther
https://doi.org/10.1007/s40487-019-00105-0
INTRODUCTION
Invasive lobular breast cancer (ILC) accounts for
10–15% of all breast cancers making it the second
most common type of breast cancer behind inva-
sive ductal carcinoma (IDC, also known as invasive
carcinoma of no special type) [1–4]. There has been
an apparent increase in the incidence of ILC over
the last 2 decades due to diagnostic advances [5, 6].
Increased incidence of ILC is associated with the
use of hormone replacement therapy in post-
menopausal patients [7–9]. Compared with IDC,
ILC tends to occur in older women [10].
Many studies show that ILC is associated with a
good prognostic phenotype, i.e., well-differenti-
ated (low grade), low-to-moderate proliferation
index, hormone receptor positivity for both
oestrogen receptor-a (ER) and progesterone recep-
tor (PR), human epidermal growth factor receptor
2 (HER2)-negativity and basal marker negative
status [11, 12]. Although the majority of ILC is ER-
positive and responds well to endocrine therapy,
retrospective clinical cohort studies show that
long-term outcomes of ILC are equivalent or even
inferior to that of IDC [13–15]. However, the evi-
dence is mixed and there are conflicting data to
suggest that adjusting for stage would abolish any
difference in long-term clinical outcome between
ILC and IDC [16]. This highlights the need for
further research into the biological basis of
observed differences between ILC and IDC, cou-
pled with prospective clinical trials aimed at
improving outcomes for patients with ILC.
This article summarises the morphological and
molecular features of ILC at presentation and how
these affect the diagnosis and management of
ILC. Current management strategy, key clinical
trials and future directions as a result of functional
study of the consequences of its unique molecular
profile are discussed in this article.
DISCUSSION
Histopathological and Molecular
Characteristics of Lobular Breast Cancer
Most ILC is classified as luminal A in terms of its
molecular subtype: ER positive, PR positive, low
proliferation index (Ki67) and HER2 negative
[11, 12]. In ILC, the basal subtype (triple nega-
tive: ER, PR and HER2 negative) occurs less fre-
quently and is linked to a distinct
‘‘pleomorphic’’ histological subtype. Classic ILC
is made up of uniform cells with spherical
nuclei and indistinct nucleoli, whereas pleo-
morphic ILC tends to consist of larger cells with
expansive eosinophilic cytoplasm [17].
The classic hallmark of ILC, found in 85–95%
of cases, is loss of E-cadherin protein expression,
which leads to its distinctive discohesive
appearance and characteristic single-file pattern
of invasive cells (see Fig. 1) [11, 18, 19]. E-cad-
herin is a calcium-dependent transmembrane
protein that mediates intercellular adhesion
and polarity by homophilic attachment to
adjacent cells; thus, loss of E-cadherin results in
loss of intercellular adhesion with detached
cells undergoing programmed cell death by
anoikis [18, 20–22].
Mechanisms of E-cadherin loss in ILC
include mutation or methylation of the CDH1
gene (located at chromosome 16q22.1) and loss
of heterozygosity in the chromosome region
16q [23–25]. Another mechanism of E-cadherin
loss is dysregulated expression of catenin-bind-
ing proteins (a, b, c and p120-catenin), which
anchor E-cadherin to the membrane and the
actin cytoskeleton [26, 27]. Downregulation of
catenin-binding protein (CBP) leads to its
cytoplasmic redistribution and makes ILC cells
resistant to anoikis. CBP downregulation also
leads to activated Rho/Rock signalling, which
CDH1 loss →
discohesive
morphology
Diagnosc uncertainty →
Less breast-conserving surgery
Contralateral mastectomy 
Therapy implicaons:ILC-disnct features:
ER(+)/PR(+)
Low Ki67
PTEN/Akt
FOXA1 mutaon
ER programme
Good endocrine therapy response
Poor chemotherapy response
Less neoadjuvant treatment
ILC
IDC E2-deprivaon over ER-modulaon?
Novel targets in hormone resistance
Fig. 1 Comparison of key molecular and histological
features of ILC and IDC and the implications for
treatment of ILC. E2 = oestradiol; PTEN/Akt refers to
PTEN loss and Akt activation; ER programme refers to
the distinct ER-mediated gene expression programme in
ILC. Adapted with permission from Ciriello et al. [12]
Oncol Ther
promotes cell migration [22, 26, 27]. These
observations suggest that CBP downregulation
enables ILC cells to survive and proliferate in
their characteristic single-file pattern.
Loss of functional E-cadherin may be asso-
ciated with epithelial-to-mesenchymal transi-
tion (EMT), although this remains
controversial. Cadherin switching in CDH1-de-
ficient tumours to N-cadherin may favour a
mesenchymal phenotype. However, since
E-cadherin loss in ILC tends to be an early
event, the association of EMT with later stages
of cancer progression suggests that E-cadherin
loss is not sufficient to cause EMT. This topic
has been extensively described by McCart Reed
and colleagues [11, 28].
Besides E-cadherin loss, ILC is enriched ver-
sus IDC for inactivating phosphatase and tensin
homologue (PTEN) alterations (14% vs. 3%),
forkhead box protein A1 (FOXA1) mutations
(7% vs. 2%) and runt-related transcription fac-
tor 1 (RUNX1) mutations (10% vs. 3%) [12]. Loss
of the tumour suppressor, PTEN, as a result of
homozygous chromosomal loss at 10q23, is
associated with increased Akt phosphorylation,
which is strongly activated in ILC, upregulates
EGFR and thus creates a more aggressive phe-
notype [12, 29–31]. Along with enrichment of
FOXA1 mutation, ILC is distinguished from IDC
by relatively low frequency of GATA3 mutations
(5% vs. 20%) [12]. FOXA1 and GATA3 are key
transcriptional regulators of ER activity [32, 33].
These findings suggest critical and mutually
exclusive roles for FOXA1 and GATA3 in the
evolution of ILC and IDC, respectively.
FoxA1 is a pioneer transcriptional factor that
opens condensed chromatin to allow ER to bind
at specific sites on the DNA, thereby inducing
cell cycle progression and tumour growth
[32, 34]. FOXA1 is a component of a gene
expression signature associated with luminal
breast tumours, which is associated with a bet-
ter prognosis [35]. FOXA1 mutations in ILC
cluster in the forkhead (DNA-binding) domain
[12, 36]. This implies that mutations may affect
the pioneer function of FoxA1 and thereby alter
ligand-dependent ER binding to DNA. FOXA1
mutations may therefore alter the response to
ER-targeted therapies such as tamoxifen, a
selective ER modulator. For example, forkhead
box mutations in FOXA1 may alter the avidity
of FoxA1 binding to DNA at specific genome
loci, thereby reprogramming genomic ER bind-
ing and leading to altered gene expression pro-
files associated with proliferation and/or
endocrine resistance [36]. These hypotheses
warrant urgent preclinical and clinical
investigation.
Diagnosis of Lobular Breast Cancer
ILC does not always present with a firm lump in
the breast and therefore poses particular chal-
lenges for its detection clinically and/or via
screening [37]. Signs of ILC may include a
thickened or swollen area in the breast with or
without a change in the nipple shape (e.g.,
inverted nipple) and dimpling of the skin [38].
Relative to other subtypes of breast cancer, the
extent of a primary ILC lesion is difficult to
assess both clinically and by mammography
because of its infiltrative growth pattern into
the stroma without desmoplastic reaction
[38, 39].
Due to its diffuse and discohesive ILC mor-
phology, ILC cannot be accurately assessed by
mammography alone [40]. Sensitivity of mam-
mography for ILC ranges from 57 to 81%
[40, 41]. Furthermore, whilst magnetic reso-
nance imaging (MRI) offers improved resolu-
tion, studies suggest that the ability of MRI to
assess suitability for breast-conserving surgery is
often suboptimal in cases of ILC [42]. In addi-
tion, compared with other subtypes, there is
evidence that synchronous contralateral (i.e.,
bilateral) primary disease occurs more fre-
quently in ILC (20.9% in ILC versus 11.2% in
IDC; p\ 0.0001) [43].
Late-presenting ILC has a distinct profile of
distant metastatic sites. In ILC, transcoelemic
spread leads to relative increase in frequency of
gastrointestinal tract, peritoneal and ovarian
metastases [13, 43, 44]. ILC that has spread to
the gastrointestinal tract may present with gas-
trointestinal upset and bowel symptoms,
including subacute and acute obstruction, while
peritoneal disease may present with ascites,
hydronephrosis and/or hydroureter. In terms of
the ‘classic’ sites of breast cancer metastases,
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there is relatively more metastasis to bone and
skin and less to lungs and brain [43, 44]. In
patients on adjuvant therapy for ILC, or those
being followed up post-adjuvant therapy,
knowing the histological subtype is crucial in
predicting the spread and monitoring for
recurrence.
Current Treatment of Primary Lobular
Breast Cancer
Current treatment for ILC follows identical
treatment protocols as for all other histological
subtypes of breast cancer [45]. This section
focuses on how known ILC-specific features
may impact surgical and medical management
(i.e., endocrine therapy and chemotherapy).
Emerging therapy modalities such as
immunomodulation—already a mainstay of
treatment in advanced breast cancer—are likely
to have an impact on primary treatment pro-
tocols in the near future [46]. Immunotherapy
is discussed further in ‘‘Future Treatment of
Lobular Breast Cancer’’).
Surgery
In most cases of breast cancer, breast-conserving
surgery by wide local excision is performed to
remove the tumour with a margin of the sur-
rounding normal tissue [45]. However, in ILC,
there is evidence that 17–65% of patients have
to undergo a second surgical intervention [47].
This raises concerns about the accuracy of ILC
assessment due to its diffuse and multifocal
morphology. Consequently, patients with ILC
are more likely to undergo breast removal by
mastectomy. Whilst offering greater resolution,
MRI scanning may also increase false-positive
detection of regional disease leading to an
inappropriate increase in rates of mastectomy
[42]. Following surgery, patients with ILC often
undergo contralateral mastectomy because of
the known tendency for bilateral ILC to occur
[48].
Despite concerns regarding the uncertainty
of complete excision of primary ILC following
breast-conserving surgery, evidence suggests
that modern surgical approaches confer the
same rates of local recurrence for ILC, IDC and
mixed histology tumours [49]. Furthermore,
evidence shows that mastectomy may not offer
a long-term survival advantage over breast-
conserving surgery [50]. These observations
imply that the rate of breast-conserving surgery
in ILC could be increased without compromis-
ing long-term clinical outcomes.
Neoadjuvant Therapy
Besides initial surgery, there is an option to
have primary systemic treatment to manage ILC
[45, 51]. Neoadjuvant chemotherapy is aimed at
improving rates of breast-conserving surgery.
However, consensus has emerged that ILC tends
to respond poorly to chemotherapy, leading to
lower disease-free and overall survival following
neoadjuvant chemotherapy compared with IDC
[52–54]. Histological evidence indicates that
ILC persists in up to 99% of cases (i.e., only
1% rate of pathological complete response)
following anthracycline-based neoadjuvant
chemotherapy [55]. The poor response to
chemotherapy is also associated with its lumi-
nal A subtype (ER/PR positive, low mitotic
index/Ki67) [53]. Neoadjuvant chemotherapy is
generally not considered for patients with ILC
as it is unlikely to improve rates of breast-con-
serving surgery but exposes patients to toxicities
that can be life threatening.
As most ILC is luminal A type and hormone
responsive, treatment with endocrine therapy
in the neoadjuvant setting may be preferable to
chemotherapy. A retrospective study of 61
patients with ER-positive ILC found that
neoadjuvant letrozole reduced tumour size by a
mean of 66% at 3 months, and the rate of suc-
cessful breast conservation was 81% [56]. This
small study demonstrates that there is untapped
potential to increase rates of breast-conserving
surgery and reduce rates of mastectomy in
ILC—especially as endocrine therapy is opti-
mised by combination with targeted therapies
such as CDK4/6 inhibitors. Specific targeted
therapies in ILC are discussed further in ‘‘Future
Treatment of Lobular Breast Cancer’’.
Adjuvant Therapy
Post-surgery, depending on prognostic risk fac-
tors and biomarker expression, patients may
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need to undergo adjuvant radiotherapy,
chemotherapy and/or endocrine therapy [45].
In high-risk cases of primary disease in which
patients receive adjuvant chemotherapy, there
is evidence that ILC has an inferior prognosis
than IDC, even after correcting for confounding
factors such as patient age and breast cancer
stage [13]. This is corroborated by studies
showing that taxane-based chemotherapy is less
effective in patients with hormone receptor
positive, low proliferation and/or lobular his-
tologic subtype tumours [57, 58]. On the other
hand, studies have consistently shown that ILC
responds well to endocrine therapy. In the
adjuvant setting, tamoxifen, a selective ER
modulator, is indicated for pre-menopausal
women, whilst post-menopausal women are
given a third-generation aromatase inhibitor
such as anastrozole or letrozole, irrespective of
the histological subtype of breast cancer (see
[59] for a recent review).
There is retrospective clinical evidence that
patients with ILC benefit less from adjuvant
tamoxifen than patients with IDC (see Fig. 2).
At 8 years of follow-up, disease-free survival on
adjuvant tamoxifen was 66% for patients with
ILC versus 75% for patients with IDC (p = 0.03)
[60]. In contrast, benefit from adjuvant letrozole
at 8 years was identical between ILC and IDC
(82% disease-free survival for both). This
implies an intrinsic resistance to tamoxifen in
ILC and that patients with ILC should be pref-
erentially offered adjuvant aromatase inhibi-
tion. A current pre-surgery window-of-
opportunity study (Clinical Trials registration
no. NCT02206984) is investigating which ER-
targeted therapy (fulvestrant vs. anastrozole vs.
tamoxifen) is most effective in ILC [61]. With
sufficient recruitment, this study could indicate
which endocrine therapy agent gives the
strongest signal of response in ILC.
There is evidence that adjuvant radiotherapy
improves survival outcomes for patients with
ILC [62–64]. However, relatively few studies
have investigated radiotherapy in the specific
context of ILC, and further study is urgently
required.
Future Treatment of Lobular Breast Cancer
In the future, the treatment of ILC may be
improved with better understanding and clinical
application of its unique molecular profile. For
example, there is evidence that amplification of
fibroblast growth factor receptor 1 (FGFR1) is a
feature specific to ILC [65, 66]. A study by Sikora
et al. found that the ILC cell line model, MM134,
is intrinsically resistant to tamoxifen and pro-
vided evidence that this could be reversed by
inhibition of FGFR1 [65]. The same in vitro study
demonstrated that in ILC, ER drives a unique
gene expression program associated with resis-
tance to tamoxifen. Subsequently, the group
showed that WNT4 (encoding a Wnt signalling
pathway ligand) was the most strongly upregu-
lated ER target gene in ILC and may represent a
novel therapeutic target to enhance response to
endocrine therapy in patients with ILC [67].
Acquired mutations in ESR1 are found in
5–25% of secondary breast tumours as a result of
selective treatment pressure leading to consti-
tutive ER activity [68–71]. Whilst ESR1 muta-
tions are relevant to the choice of therapy in
metastatic breast cancer (for example, using an
ER downregulator, i.e., fulvestrant), there is no
evidence that specific ESR1 mutations pre-exist
in primary ILC [72]. However, the unique ER-
mediated gene expression programme in pri-
mary ILC leads to the hypothesis that alteration
of ER transcriptional regulators—e.g., DNA
binding domain mutations in FOXA1 and
RUNX1—may link to endocrine resistance and
clinical outcomes in an ILC-dependent manner.
As a potential target in endocrine-resistant
breast cancer, FoxA1 is therefore a promising
future therapeutic research area for ILC [73–75].
Traditionally, transcription factors have been
considered therapeutically intractable,
although ligand-activated nuclear receptors
such as ER are the classic counterexample.
Cyclin-dependent kinase (CDK) 4/6 inhibitors,
e.g., palbociclib and ribociclib, are licensed first
line in advanced ER-positive, HER2-negative breast
cancer in combination with endocrine therapy
[76, 77]. Multiple clinical trials are investigating
the use of CDK4/6 inhibitors in the neoadjuvant
and adjuvant settings for ER-positive breast cancer.
To better understand how ILC might respond to
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neoadjuvant CDK4/6 inhibition, the Palbociclib
and Endocrine Therapy for Lobular Breast Cancer
Preoperative Study (PELOPS, Clinical Trials regis-
tration no. NCT02764541) is measuring the
pathological complete response rate after 24 weeks
of endocrine therapy with or without palbociclib
[78]. Given the relative lack of chemotherapy
response in ILC, this neoadjuvant trial (expected to
complete in2020) ispotentiallypivotal forpatients
with ILC. The trial design also incorporates a win-
dow-of-opportunity phase to test the hypothesis
that letrozole is more effective in ILC than
tamoxifen (see Fig. 3) [78].
Other strategies under clinical investigation
for ILC include ROS1 targeting with crizotinib
in advanced E-cadherin-negative, ER-positive
lobular breast cancer and diffuse gastric cancer,
known as the ROLO study (Clinical Trials reg-
istration no. NCT03620643) [79]. This trial
exploits a synthetic lethality between E-cad-
herin deficiency and inhibition of the tyrosine
kinase ROS1 [80]. Crizotinib is an existing ROS1
tyrosine kinase inhibitor licensed for use in
ROS1-positive non-small-cell lung cancer that
could in theory be repurposed for E-cadherin-
deficient cancers. If positive response rates are
seen in advanced ILC, this approach may lead to
further trials investigating ROS1 inhibition in
the adjuvant or neoadjuvant settings.
Recent evidence suggests that immune-related
gene expression defines some ILC subtypes and is
associated with survival rate [12, 81]. Compared
with IDC, there isevidencethat ILCexhibitshigher
activity of almost all types of immune cells [81]. In
this study by Du et al., evidence of lymphocytic
infiltration in ILC tumours is linked to neoadju-
vant chemotherapy response. However, a study by
Desmedt et al. shows that even though lympho-
cyte infiltration is present in ILC, it is 21% lower
than in IDC (p\0.001) [82]. In ILC, high lym-
phocyte infiltration is associated with highly
Fig. 2 Retrospective clinical evidence of a differential
response to different classes of endocrine therapy in ILC.
These data formed the basis of in vitro functional and early
clinical studies of the differences between ILC and IDC.
Kaplan-Meier plots show a disease-free survival and
b overall survival stratified by histology (ductal/lobular)
and endocrine therapy agent (letrozole, L/tamoxifen, T);
N = 2923. Reproduced with permission from Metzger
Filho et al. [60]
Clinical trial – PELOPS:
Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperave Study 
stage 1-3, ≥1.5cm, ER/PR+, HER2- ILC / IDC
letrozole tamoxifen
research biopsy
endocrine therapy +/- palbociclib
window treatment phase (2 weeks)
diagnosis
treatment phase (24 weeks)
complete pathological responsesurgery
Ki67 response
Fig. 3 PELOPS trial of neoadjuvant palbociclib, including
a window-of-opportunity phase to provide prospective
evidence on endocrine therapy of choice in ILC [78].
Study population is enriched for ILC. Treatment with
palbociclib is randomly allocated. Primary outcome mea-
sure is complete pathological response
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proliferative tumours, suggesting that there is a
subgroup of ILC likely to respond well to existing
immune checkpoint (PD-1, PD-L1 and CTLA4)
inhibitors [82].
Response of ILC tumours to immune check-
point inhibition is currentlybeing investigated ina
phase 2 clinical trial assessing the efficacy of car-
boplatin and atezolizumab in metastatic lobular
breast cancer (the GELATO study, Clinical Trials
registration no.NCT03147040) [83].Atezolizumab
is a monoclonal antibody targeting programmed
death ligand 1 (PD-L1). Its mechanism of action is
to disrupt the T cell inhibitory interaction of PD-L1
(on antigen-presenting cells) with its receptor PD-1
(on T-cells), thereby ‘‘taking the brakes off’’ the
immune response. The study also aims to find
novel markers of response to carboplatin plus ate-
zolizumab, which could be very informative for
future trials of immunotherapy in ILC.
CONCLUSION
ILC has distinct morphological features that
relate to key molecular hallmarks such as loss of
E-cadherin, which can make diagnosis and sur-
gical treatment more challenging compared
with IDC. On the other hand, ILC is charac-
terised by molecular features such as ER and PR
positivity that are associated with good clinical
outcome and response to endocrine therapy.
The challenge for the field remains to
improve our understanding of the functional
implications of the unique molecular profile of
ILC, beyond loss of E-cadherin. Linking ILC-as-
sociated molecular features with clinical phe-
notype—including response to endocrine
therapy—and developing novel therapeutic
strategies for biomarker-led and immunomod-
ulatory clinical trials will be key to improving
long-term outcomes for patients with ILC.
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